ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0QN1 Santhera Pharmaceuticals Holding Ag

190.20
0.00 (0.00%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Santhera Pharmaceuticals Holding Ag LSE:0QN1 London Ordinary Share CH1276028821 SANTHERA PHARMACEUTICALS ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 190.20 2 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 7.47M -71.08M -0.9436 -12.40 881.26M

Santhera Publishes Annual Report 2022

31/05/2023 10:50pm

GlobeNewswire Inc.


Santhera Pharmaceuticals (LSE:0QN1)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Santhera Pharmaceuticals Charts.
Santhera Publishes Annual Report 2022

Ad hoc announcement pursuant to Art. 53 LR

Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022.

Santhera’s Annual Report 2022 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2022, and confirms the preliminary unaudited 2022 annual results which were published on April 27, 2023. The Annual Report 2022 is available for download on the Company’s website at www.santhera.com/financial-reports.

Corporate calendarJune 27, 2023        Annual General Meeting

About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license for all indications worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. For vamorolone in the treatment of DMD, Santhera has a new drug application (NDA) under review by the U.S. FDA, a marketing authorization application (MAA) under review by the European Medicines Agency (EMA) and an MAA submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.

Raxone® is a trademark of Santhera Pharmaceuticals.

For further information please contact: public-relations@santhera.com orEva Kalias, Head Investor Relations & CommunicationsPhone: +41 79 875 27 80eva.kalias@santhera.com

Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment

  • 2023 05 31_AR2022_e_final

1 Year Santhera Pharmaceuticals Chart

1 Year Santhera Pharmaceuticals Chart

1 Month Santhera Pharmaceuticals Chart

1 Month Santhera Pharmaceuticals Chart